Lexeo Therapeutics (LXEO) Non-Current Assets (2022 - 2026)
Lexeo Therapeutics (LXEO) posted Non-Current Assets of $49.5 million for Q1 2026, down 38.36% sequentially from $80.3 million in Q4 2025, and up 142.43% YoY from $20.4 million in Q1 2025.
Lexeo Therapeutics (LXEO) Non-Current Assets (2022 - 2026) Analysis & Trends
Lexeo Therapeutics has reported Non-Current Assets for 5 years, with the latest figure at $49.5 million in Q1 2026.
- Quarterly Non-Current Assets rose 142.43% year-over-year to $49.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $181.8 million (up 157.93% YoY) and the FY2025 annual result came in at $80.3 million, up 285.65% from the prior year.
- Non-Current Assets retreated to $49.5 million in Q1 2026 per LXEO's latest filing, from $80.3 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $80.3 million in Q4 2025 and troughed at $14.4 million in Q3 2024.
- A 5-year average of $26.3 million and a median of $16.5 million in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets dropped 9.1% in 2024, then jumped 285.65% in 2025.
- Over 5 years, Non-Current Assets stood at $17.0 million in 2022, then decreased by 8.9% to $15.5 million in 2023, then surged by 34.22% to $20.8 million in 2024, then surged by 285.65% to $80.3 million in 2025, then plunged by 38.36% to $49.5 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $49.5 million, $80.3 million, and $16.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Lexeo Therapeutics | 397.10 Mn | 397.10 Mn | - | 36.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.99 Mn |
| Mar 31, 2026 | 49.49 Mn |
| Dec 31, 2025 | 80.30 Mn |
| Sep 30, 2025 | 16.05 Mn |
| Jun 30, 2025 | 36.01 Mn |
| Mar 31, 2025 | 20.42 Mn |
| Dec 31, 2024 | 20.82 Mn |
| Sep 30, 2024 | 14.41 Mn |
| Jun 30, 2024 | 14.86 Mn |
| Mar 31, 2024 | 15.12 Mn |
| Dec 31, 2023 | 15.51 Mn |
| Sep 30, 2023 | 15.85 Mn |
| Dec 31, 2022 | 17.03 Mn |